+34 914 524 941    info@www.algenex.com

Patent families

Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in key markets for certain aspects of our products, processes and related technologies. To this end we strive to protect our proprietary and intellectual property position by, among other methods, filing international and foreign patent applications related to multiple aspects of our products, processes and technologies. We also monitor continuously the IP space and take a proactive approach in preventing others from infringing our proprietary or intellectual property rights.
    • WO 2012/169939 A2. Recombinant DNA elements for the expression of recombinant proteins in a host cell.

    • WO 2012/168789 A2. Recombinant DNA elements for the expression of recombinant proteins in insects.

    • WO 2014/086981 A1. Baculovirus system for expressing proteins forming virus-like particles.

    • WO 2010/025764 A1. Insect-derived promoters for foreign protein expression in insect cells.

    • WO 2009/112603 A1. Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof.

    • ES 2232308A1. Device for larvae rearing.

    • ES 200703274. Device and Method for the mass culture of insect larvae.

    • WO 2009/016100. Monomeric VHH domain derived from anti-vp6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, composition, prevention and treatment methods for rotavirus infections.

    • WO2008/129103. New antiviral peptides from African swine fever virus which prevent the binding of the virus to dlc8.

    • EP 15 382 451.1. Expression of recombinant proteins in Trichoplusia ni pupae.

    • PCT/EP2016072143. Expression of recombinant proteins in Trichoplusia ni pupae.

    • EP 18 382 452.3. Vaccines for the prevention of RHDV (co-owned).